PRCN 323Alternative Names: ABCD1 gene therapy - Neuralgene; PRCN-323
Latest Information Update: 06 May 2014
At a glance
- Originator Neuralgene
- Class Adrenoleucodystrophy gene therapies; Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Adrenoleucodystrophy
Most Recent Events
- 29 Apr 2014 Clinical trials in Adrenoleucodystrophy in Mexico (Intrathecal)